-
1.发明公开ARGININE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT 审中-公开腺苷脱氨酶对ADI-PEG 20抗癌治疗的交叉反应性降低
公开(公告)号：EP3193913A1
公开(公告)日：2017-07-26
申请号：EP15842576.9
申请日：2015-09-16
申请人： Polaris Group , Showalter, Richard
发明人： SHOWALTER, Richard , ALMASSY, Robert , THOMSON, James A. , SISSON, Wes , SHIA, Wei-Jong , CHEN, Li-Chang , LEE, Yang
IPC分类号： A61K38/50
CPC分类号： A61K38/50 , A61K45/06 , A61K47/60 , C12N9/78 , C12Y305/03006
摘要： The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
摘要翻译： 本发明一般涉及分离的精氨酸脱亚氨酶（ADI）蛋白，与ADI-PEG 20相比，其具有与ADI-PEG 20抗体的交叉反应性降低，但其可具有与ADI-PEG相当或更好的功能特征 20，包含ADI蛋白的组合物，以及治疗精氨酸依赖性疾病或相关疾病例如癌症的相关方法。
-
2.发明公开
公开(公告)号：EP4104853A1
公开(公告)日：2022-12-21
申请号：EP22172372.9
申请日：2015-09-16
申请人： Polaris Group
发明人： SHOWALTER, Richard , ALMASSY, Robert , THOMSON, James A. , SISSON, Wes , SHIA, Wei-Jong , CHEN, Li-Chang , LEE, Yang
摘要： The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
-
3.发明公开ARGININE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT 审中-公开精氨酸脱亚氨酶具有减少交叉反应反对ADI-PEG20抗体治疗癌症
公开(公告)号：EP2968482A2
公开(公告)日：2016-01-20
申请号：EP14769340.2
申请日：2014-03-13
申请人： Polaris Group
发明人： ALMASSY, Robert , SHOWALTER, Richard E. , THOMSON, James A. , SISSON, Wes , SHIA, Wei-Jong , CHEN, Li-Chang , YANG, Lee
CPC分类号： A61K38/50 , A61K45/06 , C12N9/78 , C12Y305/03006
摘要： The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
-
-
搜索结果
3 条记录 (耗时 0.01 秒)
